News

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.
Long-lasting HIV prevention shot headed toward approval
FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.
A new shot prevents HIV—and breathes new life into a stagnant biotech
Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...
Long-lasting HIV prevention shot heads toward approval
A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.
Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"
NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...
Trump administration ending multiple HIV vaccine studies, scientists and officials say
The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...
2 Reasons to Like GILD (and 1 Not So Much)
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...
Monitor on MSN6d
Gilead pushes on with HIV drug for poor nations despite funding crisis
Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...
Jefferies Maintains Buy Rating on Gilead Sciences (GILD), Cites Robust Pipeline
Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...
BioSpace5d
FDA Action Alert: Merck, Moderna, Gilead, Regeneron/Sanofi and More
Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...
Morgan Stanley Reaffirms Overweight on Gilead Sciences, Inc. (GILD), Citing LEN Potential
On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while ...
pharmaphorum1d
Gilead's HIV success and controversy: Expanding access amid criticism
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...